John W. Walsh Alpha-1 Home Infusion Act of 2025

Bill 119 hr 2343, also known as the Alpha-1 Antitrypsin Deficiency Treatment Act, aims to amend title XVIII of the Social Security Act to include coverage and payment for treatment of Alpha-1 Antitrypsin Deficiency Disorder under part B of the Act. This genetic disorder affects the liver and lungs, leading to serious health complications.

The bill seeks to ensure that individuals with Alpha-1 Antitrypsin Deficiency Disorder have access to necessary treatments and medications through Medicare Part B. This would help alleviate financial burdens for patients and improve their quality of life.

In addition to providing coverage for treatment, the bill also includes provisions for research and education on Alpha-1 Antitrypsin Deficiency Disorder. This would help increase awareness of the disorder and improve diagnosis and treatment options for affected individuals. Overall, Bill 119 hr 2343 aims to address the needs of individuals with Alpha-1 Antitrypsin Deficiency Disorder by expanding Medicare coverage for treatment and supporting research and education efforts related to the disorder.